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Abstract
Background: About 10 million children worldwide live or work on the street. International reports estimate the prevalence of
substance use among street children to be between 25% - 90%, which is who were referredntal disorders and high-risk behaviors.
Objectives: The objective of this study was to report the outcomes of assisted withdrawal of opioid-dependent vulnerable children
and adolescents who were referred to child and adolescent psychiatric ward of Ali Ebne Abitaleb hospital, an academic hospital in
Zahedan city.
Methods: Clinical chart abstractions were performed on a convenience sample of 40 serial opioid-dependent street children and
adolescents (mean age: 11.14± 3.6 years) who were referred to child and adolescent psychiatric ward of Ali Ebne Abitaleb treatment
and research center from November 2014 to May 2015. The demographic data, drug use history, comorbid physical and psychiatric
conditions, symptomatology of opioid withdrawal syndrome, pharmacotherapies and psychosocial services, length of hospital stay,
and any adverse events were extracted from the patients’ files using a checklist developed by the authors.
Results: Twenty-four (60%) patients were male, and 16 (40%) were female. The main drug used by all patients was opioids. Heroin
Kerack (which has a street name of crystal in southeast Iran) was the most common (75%) drug of use, followed by opium (10%) and
opium residue (7.5%). None of the participants self-reported using injected drugs. The high rate of a lack of eligibility for guardian-
ship was documented among parents (87.5%) mainly due to their use of illegal drugs. Musculoskeletal pain and diarrhea were the
most common withdrawal symptoms of the patients upon admission. The mean length of stay was 10.8 (± 7.30) days, and no sig-
nificant adverse events were reported during the symptomatic treatment of opioid withdrawal syndrome.
Conclusions: To our knowledge, this is the first study to report on the safety and feasibility of inpatient symptomatic pharmaco-
logical treatment for assisted withdrawal among opioid-dependent children and adolescents in Iran. More well-designed studies
to investigate the long-term outcomes of opioid treatment among children are warranted.
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1. Background
Tens of millions of children around the world work or
live on the street (1). It has been estimated that about 25% -
90% of street children (which was defined as people under
18 years of age) who live or work on the streets (2) use drugs
in their daily lives (3). A recent meta-analysis of 22 studies
from 22 low-income countries reported that 60% of street
children have a lifetime history of drug use; inhalants were
the most common substances used, followed by tobacco,
alcohol, and marijuana (4). Most of these street children
initiate their substance use with alcohol, tobacco, and in-
halants due to the legal availability of these substances (4-
7). Factors such as age, sex, duration of time spent on the
street, and social systems affect the pattern of substance
use among street youth (8).
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High rates of substance use involvement among street
children in Iran have been documented in several studies.
One investigation on street children recruited from vari-
ous areas of Tehran showed a lifetime prevalence of smok-
ing of 36%, while the rates at which street children use
alcohol and other substances were 8% and 3 - 4%, respec-
tively; these The treatment setting was child more preva-
lent among boys than girls (9). Because of their lifestyle,
street children are exposed to sexual and physical abuse,
which leaves them susceptible to mental disorders, such as
post-traumatic stress disorder (PTSD) and depression (10).
Ghasemzade (2003) reported high rates (37%) of addiction,
selling drugs (41%), depression (45%), a lifetime history of
sexual abuse (50%), and physical health problems, includ-
ing skin lesions (82%), low weight and height (80%), and
anemia (84%), among 75 street children aged 14 - 19 in 2001
in Tehran (11).
Despite high rates of substance use disorders among
street children, there is little evidence regarding the stan-
dard treatment for this sub-population in terms of the
treatment setting and modalities. While it has been ac-
cepted that the treatment of children with substance use
disorders should take place in less restrictive settings than
those traditionally recommended for adults (12, 13), unique
factors among these children, such as substance use within
the family, the high rate of comorbid conditions, and the
low willingness and motivation of parents or caregivers to
cooperate with treatment, necessitate the use of inpatient
settings.
The Iranian government ratified regulations for ad-
dressing the multidimensional needs of street children in
2005. These regulations define a street child as someone
under 18 years of age who for a limited or unlimited period
of time lives on the street, including either children who
are in contact with their families and have a home to return
to or children who make the street their home and have
minimal or no relationship with their families. According
to these regulations, the state welfare organization (SWO)
is considered the main organization for providing housing
and support services in Iran and also coordinates 10 other
organizations, which are appointed to provide a range of
services from legal assistance to healthcare (14).
Following some reports on the high prevalence of sub-
stance use among street children in Zahedan city, the drug
control coordinating councils of the Sistan and Balouches-
tan provinces, the provincial welfare organization, and Za-
hedan University of Medical Sciences (ZUMS) implemented
an urgent plan for police to gather street children and
transfer them to foster care centers of local welfare organi-
zations. Any children who suffered from withdrawal symp-
toms should be referred to child and adolescent psychi-
atric ward of Ali Ebne Abitaleb Hospital, which is affiliated
with ZUMS.
2. Objectives
Here, we present the preliminary results of inpatient




The treatment setting was child and adolescent psychi-
atric ward of Ali Ebne Abitaleb academic general hospital.
The ward consisted of 10 beds in four rooms, one isolation
room, one playroom equipped with a television (TV) and
toys, and one time-out room. All rooms and corridors of
the ward were monitored by closed-circuit TV.
The ward was staffed with eight nurses, five nursing
aides, and one master-level clinical psychologist, who pro-
vided treatment services for the study participants under
the direct supervision of one child and adolescent psychia-
trist. This is an academic ward of child and adolescent psy-
chiatry that occasionally includes rotating residents who
are completing their adult general psychiatric training at
ZUMS. Only one such resident participated in the treat-
ment of the study participants during the study period.
The child and adolescent psychiatric outpatient clinic
of the hospital is active four days per week and provided
aftercare services for these patients after they were dis-
charged from the ward.
3.2. Participants
Data were extracted from the inpatient files of the first
40 serial cases of street opioid-dependent children admit-
ted to child and adolescent psychiatric ward of Ali Ebne
Abitaleb treatment and research center, which was affili-
ated with ZAUMS, in Zahedan, the center of the Sistan and
Balouchestan provinces in southeast Iran, from November
2014 to May 2015. The study participants were children
who had been detained by the police because they lived
or worked on the street; the children were transferred to
the foster care center of the SWO because of their parents’
incompetency for guardianship, which was mainly due to
substance use disorders. At the foster care center, children
and adolescents who were identified as being in need of
treatment for a substance use disorder were referred to
child and adolescent psychiatric ward. The study partic-
ipants were all under the guardianship of the province’s
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attorney general and were therefore referred to the hos-
pital with a court order that provided consent for all nec-
essary treatment interventions. The procedures and treat-
ment services of the ward were explained to all partici-
pants older than 7 years, and their informed consent was
obtained. The study was approved by the ethics committee
of ZAUMS.
All admitted patients were under 17 years old. A major-
ity of the participants had families and a regular dwelling,
patients was opioids. did not and/or spent the night in
places not intended as residences, such as the street, parks,
or abandoned buildings. The common characteristic of
all participants was spending many hours each day on the
streets.
Complete personal and familial histories were taken
after admission. Mental and physical examinations were
also conducted. The current substance dependence dis-
order was diagnosed based on DSM-IV-TR criteria and evi-
dence of actively using a substance within the last 30 days.
Clonidine, ibuprofen, and hydroxyzine were used for
the symptomatic treatment of opioid withdrawal. In this
study, clonidine was initiated at 0.1 mg/per day in two di-
vided doses, and then the dose was increased to 0.4 mg/day
given in 2 - 3 divided doses based on the severity of the with-
drawal symptoms on days 2 - 4 following admission. All
clonidine doses were delivered after blood pressure had
been controlled, which was indicated by a systolic blood
pressure > 90 mmHg. The participants’ assisted with-
drawal regimens were chosen based on the severity of their
withdrawal symptoms.
Complaints of musculoskeletal pain were managed
with ibuprofen. Either syrup or tablet formulations of
ibuprofen were prescribed at doses of 4 - 10 mg/kg four to
six times a day with a maximum dose of no more than 1200
mg/day. Hydroxyzine was administered at a dose of 1 mg/kg
three to four times per day to control nausea and insom-
nia. Patients who developed severe diarrhea and/or vom-
iting received rehydration treatment via a half-normal in-
travenous saline solution.
Some children suffered from comorbid physical and
psychiatric disorders. This group received additional phar-
macotherapies based on the type of comorbidity. The study
participants also were provided with psycho-education for
coping with cravings and anger management.
3.3. Data Extraction and Analysis
Data were gathered through psychiatric interviews
and physical examinations. The withdrawal symptoms
were documented by an child and adolescent psychiatrist,
who also performed the children’s physical examinations.
The study data were analyzed using the statistical pack-
age for the social sciences (SPSS), version 20, with the Chi-
squared test. All analyses were two-tailed, and a P-value <
0.05 was considered statistically significant.
4. Results
Forty consecutively admitted, opioid-dependent street
children’s and adolescents’ clinical charts were reviewed.
Twenty-four (60%) patients were male, and 16 (40%) were
female. The mean age of the participants was 11.14± 3.60
years, with a range from 9 months to 17 years. Thirty-eight
(95%) of the children reported having stable housing, while
2 (5%) did not. The parents of 35 (87.5%) of the study partici-
pants did not show competency for parenting or guardian-
ship of them at the time of the study. The parenting eligi-
bility was determined by a court order before the children
were referred to our hospital. Two (0.5%) patients admit-
ted a previous history of criminal involvement. A high in-
cidence of a low educational level was documented among
the participants’ parents, with 55% of their fathers and
67.5% of their mothers being illiterate. The demographic
characteristics of the participants by gender and age (less
than 12 years of age and 12 years and older) are presented
in Tables 1 and 2.
Among the 40 patients, 38 were experiencing opioid
withdrawal at the time of hospital admission; the remain-
ing 2 were not because there had been an interval of a few
days between their incarceration and hospital admission.
The main problem drug for all patients was opioids. The
heroin Kerack (which goes by the street name of crystal in
southeast Iran) was the most common (70%) drug of use,
followed by opium (10%) and opium residue (7.5%). The
main drug of use was not significantly different according
to gender or age group (P > 0.05) (Table 2).
Significant comorbid physical and mental health prob-
lems were observed in 9 (22.5%) patients; 5 (12.5%) had
psychiatric comorbidities. One child was diagnosed with
bipolar mood disorder with psychotic features. He had
a history of childhood physical and sexual abuse and
suicidal attempts. He did not show progress on poly-
psychopharmacotherapy and finally received eight ses-
sions of electroconvulsive therapy during his hospital stay.
One child had amphetamine-type stimulant-induced psy-
chosis. One participant each was diagnosed with atten-
tion deficit hyperactivity disorder (ADHD) alone and con-
duct disorder alone, while another child suffered from
both ADHD and conduct disorder concurrently. Four (10%)
had significant physical comorbidities, including 1 (2.5%)
seizure disorder, 2 (5%) pneumonia and 1 (2.5%) endo-
carditis superimposed on a ventricular septal defect (VSD).
Twenty-two (55%) had pediculosis, which was treated with
1% Lindane shampoo and hair dressings.
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Table 1. The Demographic Characteristics of the Study Participants and their Parents by Sex and Agea
Demographic Variables Total Female Male P-Value Under 12 years 12 years andOlder P-Value
Study Participants
Age,mean± SD 11.14± 3.60 11.18± 2.58 11.11± 4.20 > 0.05 50 50 -
Religion > 0.05 > 0.05
Shia (Shiites) 75 87.5 66.6 75 75
Sunni 25 12.5 33.3 25 25
Education > 0.05 0.001
None 37.5 37.5 37.5 55 20
Primary School (Grades 1 - 5) 30.0 43.8 20.8 30 30
Secondary School (Grades 6 - 8) 10.0 18.8 29.2 0 50
Unspecified 7.5 0 12.5 15 0
Homeless 5 0 8.3 > 0.05 0 10 > 0.05
Previous History of Incarceration 5 6.3 4.2 > 0.05 2.5 2.5 > 0.05
Parents of the Study Participants
Legal Competency for Guardianship > 0.05 > 0.05
Eligible 12.5 0 20.8 5 20
Ineligible 87.5 100 79.2 95 80
Father > 0.05 > 0.05
Deceased 12.5 6.3 16.7 5 20
Living 87.5 93.7 83.3 95 80
Education > 0.05 0.030
None 55 62.5 50 80 30
Primary School (Grades 1 - 5) 15 18.8 12.5 5 25
Secondary School (Grades 6 - 8) 2.5 0 4.2 0 5
Unspecified 15 12.5 16.7 10 20
Mother > 0.05 > 0.05
Deceased 2.5 0 4.2 5 0
Alive 97.5 100 95.8 95 100
Education > 0.05 > 0.05
None 67.5 81.3 58.3 75 60
Primary School (Grades 1 - 5) 7.5 6.3 8.3 5 10
Secondary School (Grades 6 - 8) 10.0 0 16.7 10 10
Unspecified 12.5 12.5 12.5 5 20
aValues are expressed as % unless otherwise indicated.
The mean length of hospital stay was 10.8 ± 7.30 (2 -
48) days, and the mean duration of withdrawal signs and
symptoms was 1.63± 0.94 days (a few hours-3 days). Mus-
culoskeletal pain and diarrhea were the most commonly
reported withdrawal symptoms during the hospital stay.
Withdrawal signs and symptoms were not significantly dif-
ferent by gender or age group (P > 0.05). Furthermore,
there was no significant relationship between the duration
of withdrawal and gender or age group (P > 0.05) (Table 3).
5. Discussion
The present study was conducted in 40 street children
and adolescents who used drugs and had been referred to
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Table 2. Pattern of Drug Use and Comorbiditiesa
Demographic Variables Total Female Male P-Value Under 12 Years 12 Years andOlder P-Value
Main Drug of Use > 0.05 > 0.05
Heroin 5.0 6.3 4.2 5 15
Opium 10.0 6.3 12.5 5 15
Opium residue (Shireh) 7.5 0 12.5 10 5
Tramadol 0 0 0 0 0
Methadone 2.5 0 4.2 5 0
Heroin Kerack 75.0 87.6 64.9 75 75
Polysubstance Use > 0.05 > 0.05
No 65.0 43.7 79.2 75 55
Yes 35.0 56.3 20.8 25 45
Two drugs 27.5 43.8 16.7 15 40
Three drugs 7.5 12.5 4.2 10 5
Polysubstance Forms > 0.05 > 0.05
Heroin Kerack + Opium 35.7 36.3 33.3 40 33.4
Heroin Kerack + Methamphetamine 28.5 27.3 33.3 40 22.2
Heroin Kerack + Opium residue 14.2 9.1 33.3 0 22.2
Heroin Kerack + Cannabis 7.1 9.1 0 0 11.1
Heroin Kerack + Opium + Opium residue 7.1 9.1 0 0 11.1
Heroin Kerack + Opium + Heroin 7.1 9.1 0 20 0
Route of Administration > 0.05 > 0.05
Smoking 85 100 79.1 80 95
Swallowing 15 0 20.9 20 5
Sniffing 0 0 0 0 0
Injecting 0 0 0 0 0
Comorbid Conditions > 0.05 > 0.05
No 77.5 87.5 70.8 85 70
Yes 22.5 12.5 29.2 15 30
Physical (Other than pediculosis) 10.0 6.3 12.5 5 15
Psychiatric 12.5 6.3 16.7 10 15
No. of Previous Hospitalizations > 0.05 > 0.05
Zero 97.5 100 95.8 100 95
One 0 0 0 0 0
Two 2.5 0 4.2 0 5
aValues are expressed as %.
a psychiatric ward for children and adolescents. Although
a small percentage of these children perceived themselves
as homeless, we documented other factors, such as the
death or lack of a qualified guardian and parental illiteracy
or a very low literacy level, which could have contributed to
the participants’ situation as substance-using youth. This
observation is consistent with international studies that
have reported the complex needs of families referred to
child welfare services because of parental substance use
and child neglect (15-17). The high rate of parenting incom-
petency indicates that any medical and psychiatric inter-
ventions initiated among this population must be imple-
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Table 3. Signs and Symptoms of Opioid Withdrawal Syndrome Among Participantsa
Demographic Variables Total Female Male P-Value Under 12 Years 12 years andOlder P-Value
Signs and symptoms > 0.05 > 0.05
Musculoskeletal pain 77.5 87.5 70.8 70 85
Diarrhea 47.5 62.5 33.3 45 50
Runny nose 27.5 43.7 16.6 30 25
Sneezing 22.5 31.2 16.6 25 20
Abdominal pain 20 37.5 8.3 20 20
Yawning 12.5 12.5 16.6 20 15
Restlessness 17.5 0 29.1 15 15
Aggression 7.5 0 12.5 5 10
Drowsiness 2.5 0 4.1 5 0
Duration of theWithdrawal Syndrome (Days) > 0.05 > 0.05
Mean± SD 1.63± 0.94 1.68± 0.94 1.59± 0.95 1.66± 0.96 1.60± 0.94
Range 0 - 3 0 - 3 0 - 3 0 - 3 0 - 3
aValues are expressed as % unless otherwise indicated.
Table 4. Treatment Servicesa
Demographic Variables Total Female Male P-Value Under 12 Years 12 Years andOlder P-Value
Length of hospital stay, days > 0.05 > 0.05
Mean± SD 10.80± 7.30 9.94± 5.06 11.38± 8.53 9.40± 3.81 12.20± 9.52
Range 2 - 48 2 - 23 3 - 48 2 - 15 3 - 48
Pharmacotherapies
Withdrawalmanagement > 0.05
Clonidine 75.0 100 52.5 70 80
NSAIDs (ibuprofen) 75.0 87.5 70.8 55 90
Hydroxyzine 70.0 68.7 70.8 50 90
Benzodiazepines (Lorazapam, clonazepam) 7.5 0 12.5 10 5
Methadone 10.0 0 16.6 0 0
No medication 2.5 0 4.1 5 0
Other pharmacotherapies > 0.05 > 0.05
Olanzapine 7.5 0 12.5 10 5
Risperidone 12.5 0 20.8 10 15
VPA 7.5 12.5 4.1 0 15
CBZ 2.5 0 4.1 0 5
Psychosocial Services > 0.05 > 0.05
Coping with craving and anger
management psycho-education
95 93.8 95.8 90 100
aValues are expressed as % unless otherwise indicated.
mented within the context of a comprehensive program
to provide parental substance abuse treatment, psychoso-
cial support, literacy education initiatives, legal assistance,
and foster care.
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In this study, most (75%) patients were taking heroin
Kerack, followed by opium and opium residue; the most
common route of administration was smoking, which
was inconsistent with international studies that have re-
ported inhalants, tobacco and alcohol (4), and metham-
phetamine (18, 19) as the most commonly used substances
by street children in different countries. This variation may
be explained by the ease of availability of opioids in the
Sistan and Balouchestan province of Iran due to the prox-
imity of Afghanistan, the main producer of illegal opioids
in the world. All study participants used drugs through
routes other than injection, which was in line with find-
ings from other low-income countries (8, 20). About one-
third of these children had used more than one substance,
which reflects a high intensity of drug involvement in this
population.
Musculoskeletal pain, diarrhea, and runny nose were
the most common signs and symptoms observed dur-
ing the withdrawal period; there was no significant dif-
ference in withdrawal length or symptomatology by age
and gender. For the medical management of withdrawal,
clonidine, ibuprofen, and hydroxyzine were the most fre-
quently used medications. The symptomatic treatment of
opioid withdrawal was well tolerated by the children, and
no severe adverse events were seen.
One head-to-head trial that compared clonidine and
buprenorphine in a community-based treatment pro-
gram for opioid dependence among adolescents showed
a higher efficacy for buprenorphine in terms of treat-
ment retention and negative urine tests (21). Little evi-
dence exists regarding the use of maintenance medica-
tions to treat opioid dependence. Methadone mainte-
nance treatment for opioid dependence among patients
younger than 18 years is highly regulated, and its use is lim-
ited to very severe cases (22). In addition, buprenorphine
might have some advantages over methadone in terms
of its adverse effects. In a multi-site trial of adolescents
and young adults, buprenorphine maintenance increased
retention and decreased opioid-positive urine tests com-
pared to patients who received two weeks of buprenor-
phine detoxification only (23). Another case series study
indicated the feasibility and safety of community-based
extended-release naltrexone shots that were given to ado-
lescents and young adults each month for four months
in a community-based setting (24). The use of pharma-
cotherapies to manage pediatric opioid withdrawal is in
its early stages in Iran. More studies are currently needed
to determine the status of opioid pharmacotherapies for
symptomatic withdrawal in terms of their effectiveness
and costs.
The high rate of comorbid physical and psychiatric dis-
orders observed in this study has important clinical im-
plications. First, a clinician working with street children
might encounter substance use issues that co-occur with
other mental disorders and therefore should be prepared
for this possibility. Second, the identification and treat-
ment of physical health issues are crucial while working
with this population. A trend toward higher levels of physi-
cal and psychiatric comorbidities was seen among boys in
this clinical sample, which was not significant due to the
small sample size. More studies with larger sample sizes
will therefore be needed to determine any differences in
the pattern of comorbidities.
Practical implementation issues identified in this
study included work load, costs, insurance coverage, ad-
ministrative issues, and insufficient inter-sectoral collab-
oration. Cost and insurance coverage issues were also
prominent. There were limitations of this study, includ-
ing its observational design without a control group, the
absence of standardized questionnaires to monitor out-
comes, and limitations of the outcomes to the inpatient pe-
riod.
The study suggests that inpatient withdrawal manage-
ment with clonidine, antihistamines, and non-steroidal
anti-inflammatory drugs could be feasible for and well
tolerated by children and adolescents with opioid depen-
dence during the inpatient period. To develop standards of
care for opioid treatment in this population, further stud-
ies that test the efficacy of opioids agonist medications on
the severity of withdrawal, the length of stay, and the suc-
cess rate of post-discharge treatment follow-ups are war-
ranted.
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